149 related articles for article (PubMed ID: 15556755)
1. Active site binding modes of the beta-diketoacids: a multi-active site approach in HIV-1 integrase inhibitor design.
Dayam R; Neamati N
Bioorg Med Chem; 2004 Dec; 12(24):6371-81. PubMed ID: 15556755
[TBL] [Abstract][Full Text] [Related]
2. Salicylhydrazine-containing inhibitors of HIV-1 integrase: implication for a selective chelation in the integrase active site.
Neamati N; Hong H; Owen JM; Sunder S; Winslow HE; Christensen JL; Zhao H; Burke TR; Milne GW; Pommier Y
J Med Chem; 1998 Aug; 41(17):3202-9. PubMed ID: 9703465
[TBL] [Abstract][Full Text] [Related]
3. Rational design of novel diketoacid-containing ferrocene inhibitors of HIV-1 integrase.
da Silva CH; Del Ponte G; Neto AF; Taft CA
Bioorg Chem; 2005 Aug; 33(4):274-84. PubMed ID: 16023487
[TBL] [Abstract][Full Text] [Related]
4. Dissecting Tn5 transposition using HIV-1 integrase diketoacid inhibitors.
Czyz A; Stillmock KA; Hazuda DJ; Reznikoff WS
Biochemistry; 2007 Sep; 46(38):10776-89. PubMed ID: 17725323
[TBL] [Abstract][Full Text] [Related]
5. Tn5 transposase as a useful platform to simulate HIV-1 integrase inhibitor binding mode.
Barreca ML; Ortuso F; Iraci N; De Luca L; Alcaro S; Chimirri A
Biochem Biophys Res Commun; 2007 Nov; 363(3):554-60. PubMed ID: 17889829
[TBL] [Abstract][Full Text] [Related]
6. Beta-diketo acid pharmacophore hypothesis. 1. Discovery of a novel class of HIV-1 integrase inhibitors.
Dayam R; Sanchez T; Clement O; Shoemaker R; Sei S; Neamati N
J Med Chem; 2005 Jan; 48(1):111-20. PubMed ID: 15634005
[TBL] [Abstract][Full Text] [Related]
7. Modeling, analysis, and validation of a novel HIV integrase structure provide insights into the binding modes of potent integrase inhibitors.
Chen X; Tsiang M; Yu F; Hung M; Jones GS; Zeynalzadegan A; Qi X; Jin H; Kim CU; Swaminathan S; Chen JM
J Mol Biol; 2008 Jul; 380(3):504-19. PubMed ID: 18565342
[TBL] [Abstract][Full Text] [Related]
8. Active site binding modes of curcumin in HIV-1 protease and integrase.
Vajragupta O; Boonchoong P; Morris GM; Olson AJ
Bioorg Med Chem Lett; 2005 Jul; 15(14):3364-8. PubMed ID: 15950462
[TBL] [Abstract][Full Text] [Related]
9. Rational design and synthesis of novel dimeric diketoacid-containing inhibitors of HIV-1 integrase: implication for binding to two metal ions on the active site of integrase.
Long YQ; Jiang XH; Dayam R; Sanchez T; Shoemaker R; Sei S; Neamati N
J Med Chem; 2004 May; 47(10):2561-73. PubMed ID: 15115398
[TBL] [Abstract][Full Text] [Related]
10. Exploring binding mode for styrylquinoline HIV-1 integrase inhibitors using comparative molecular field analysis and docking studies.
Ma XH; Zhang XY; Tan JJ; Chen WZ; Wang CX
Acta Pharmacol Sin; 2004 Jul; 25(7):950-8. PubMed ID: 15210071
[TBL] [Abstract][Full Text] [Related]
11. Triketoacid inhibitors of HIV-integrase: a new chemotype useful for probing the integrase pharmacophore.
Walker MA; Johnson T; Ma Z; Banville J; Remillard R; Kim O; Zhang Y; Staab A; Wong H; Torri A; Samanta H; Lin Z; Deminie C; Terry B; Krystal M; Meanwell N
Bioorg Med Chem Lett; 2006 Jun; 16(11):2920-4. PubMed ID: 16546383
[TBL] [Abstract][Full Text] [Related]
12. Dynamic receptor-based pharmacophore model development and its application in designing novel HIV-1 integrase inhibitors.
Deng J; Lee KW; Sanchez T; Cui M; Neamati N; Briggs JM
J Med Chem; 2005 Mar; 48(5):1496-505. PubMed ID: 15743192
[TBL] [Abstract][Full Text] [Related]
13. A platform for designing HIV integrase inhibitors. Part 2: a two-metal binding model as a potential mechanism of HIV integrase inhibitors.
Kawasuji T; Fuji M; Yoshinaga T; Sato A; Fujiwara T; Kiyama R
Bioorg Med Chem; 2006 Dec; 14(24):8420-9. PubMed ID: 17005407
[TBL] [Abstract][Full Text] [Related]
14. Mining the NCI antiviral compounds for HIV-1 integrase inhibitors.
Deng J; Kelley JA; Barchi JJ; Sanchez T; Dayam R; Pommier Y; Neamati N
Bioorg Med Chem; 2006 Jun; 14(11):3785-92. PubMed ID: 16460953
[TBL] [Abstract][Full Text] [Related]
15. Design and synthesis of novel dihydroquinoline-3-carboxylic acids as HIV-1 integrase inhibitors.
Sechi M; Rizzi G; Bacchi A; Carcelli M; Rogolino D; Pala N; Sanchez TW; Taheri L; Dayam R; Neamati N
Bioorg Med Chem; 2009 Apr; 17(7):2925-35. PubMed ID: 19026554
[TBL] [Abstract][Full Text] [Related]
16. Diketo acid pharmacophore. 2. Discovery of structurally diverse inhibitors of HIV-1 integrase.
Dayam R; Sanchez T; Neamati N
J Med Chem; 2005 Dec; 48(25):8009-15. PubMed ID: 16335925
[TBL] [Abstract][Full Text] [Related]
17. Structural and theoretical studies of [6-bromo-1-(4-fluorophenylmethyl)-4(1H)-quinolinon-3-yl)]-4-hydroxy-2-oxo-3-butenoïc acid as HIV-1 integrase inhibitor.
Vandurm P; Cauvin C; Guiguen A; Georges B; Le Van K; Martinelli V; Cardona C; Mbemba G; Mouscadet JF; Hevesi L; Van Lint C; Wouters J
Bioorg Med Chem Lett; 2009 Aug; 19(16):4806-9. PubMed ID: 19556126
[TBL] [Abstract][Full Text] [Related]
18. Active site binding modes of dimeric phloroglucinols for HIV-1 reverse transcriptase, protease and integrase.
Gupta P; Kumar R; Garg P; Singh IP
Bioorg Med Chem Lett; 2010 Aug; 20(15):4427-31. PubMed ID: 20594846
[TBL] [Abstract][Full Text] [Related]
19. A platform for designing HIV integrase inhibitors. Part 1: 2-hydroxy-3-heteroaryl acrylic acid derivatives as novel HIV integrase inhibitor and modeling of hydrophilic and hydrophobic pharmacophores.
Kawasuji T; Yoshinaga T; Sato A; Yodo M; Fujiwara T; Kiyama R
Bioorg Med Chem; 2006 Dec; 14(24):8430-45. PubMed ID: 17010623
[TBL] [Abstract][Full Text] [Related]
20. A docking study of L-chicoric acid with HIV-1 integrase.
Healy EF; Sanders J; King PJ; Robinson WE
J Mol Graph Model; 2009 Jan; 27(5):584-9. PubMed ID: 19004651
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
